Breaking News

Financial Report: Gilead Sciences

April 23, 2014

Revenues up 97% driven by Sovaldi sales

Gilead Sciences
1Q Revenues: $5.0 billion (+97%)

1Q Earnings: $2.2 billion (+210%)

Comments: Antiviral product sales were up 119% to $4.5 billion, driven by Hepatitis C drug Sovaldi, which launched in December 2013 and had $2.3 billion in sales. Stribild sales were up 134% to $215.3 million and Complera/Eviplera sales were up 69% to $250.7 million.Cardiovascular product sales increased to $234.5 million, up 9% primarily driven by Ranexa sales.